miltefosine has been researched along with Brain Neoplasms in 3 studies
miltefosine: hexadecyl phosphocholine derivative of cisplatin; did not substantially activate HIV long terminal repeat; less toxic than cisplatin
miltefosine : A phospholipid that is the hexadecyl monoester of phosphocholine.
Brain Neoplasms: Neoplasms of the intracranial components of the central nervous system, including the cerebral hemispheres, basal ganglia, hypothalamus, thalamus, brain stem, and cerebellum. Brain neoplasms are subdivided into primary (originating from brain tissue) and secondary (i.e., metastatic) forms. Primary neoplasms are subdivided into benign and malignant forms. In general, brain tumors may also be classified by age of onset, histologic type, or presenting location in the brain.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 7.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| "Hexadecylphosphocholine (HePC) or miltefosine based proapoptotic lipid nanovesicles encapsulating paclitaxel for synergistic anticancer effect of paclitaxel and miltefosine in chemoresistant human glioblastoma multiforme (U-87 MG) overexpressing multidrug resistance 1 (MDR1) gene product P-glycoprotein (P-gp), were developed in this study." | 3.79 | Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy. ( Banerjee, R; Joshi, N; Shanmugam, T; Thakur, A, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 1 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Sandbhor, P | 1 |
| Goda, JS | 1 |
| Mohanty, B | 1 |
| Chaudhari, P | 1 |
| Dutt, S | 1 |
| Banerjee, R | 2 |
| Thakur, A | 1 |
| Joshi, N | 1 |
| Shanmugam, T | 1 |
| Zeller, WJ | 1 |
| Bauer, S | 1 |
| Remmele, T | 1 |
| Wowra, B | 1 |
| Sturm, V | 1 |
| Stricker, H | 1 |
3 other studies available for miltefosine and Brain Neoplasms
| Article | Year |
|---|---|
Bio-polymeric transferrin-targeted temozolomide nanoparticles in gel for synergistic post-surgical GBM therapy.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Delayed-Action Preparations; Glioblastoma; Glioma; Hydro | 2022 |
Proapoptotic miltefosine nanovesicles show synergism with paclitaxel: Implications for glioblastoma multiforme therapy.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Blood-Brain Barrier; Brain Neoplasms; Cell | 2013 |
Interstitial chemotherapy of experimental gliomas.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Drug Carriers; Drug Screening Assays, Antitumor; Gl | 1990 |